Coherus Oncology will release Q2 2025 financial results on August 7, 2025, followed by a conference call at 5:00 p.m. EDT.
Quiver AI Summary
Coherus Oncology, Inc. announced that it will release its second quarter 2025 financial results on August 7, 2025, after market close. Following the release, Coherus' management will hold a conference call at 5:00 p.m. EDT to discuss the results and provide a business update, with a webcast available for replay on their investor relations website. Coherus is a commercial-stage oncology company known for its PD-1 inhibitor, LOQTORZI®, and has a pipeline with promising therapies targeting various cancers. The company is focused on growing LOQTORZI sales and advancing its innovative pipeline, which includes candidates currently in clinical trials for solid tumors.
Potential Positives
- Coherus Oncology is demonstrating transparency and investor engagement by scheduling a conference call to discuss their financial results, allowing stakeholders to gain insights into the company's performance.
- The company is highlighting its innovative products and promising pipeline, particularly the approved PD-1 inhibitor LOQTORZI and its ongoing clinical candidates, which could suggest growth potential and market relevance.
- The press release provides multiple avenues for investors and interested parties to access important information about the company, enhancing accessibility and compliance with disclosure obligations.
Potential Negatives
- The company's upcoming financial results announcement may raise concerns about its financial performance, especially if the market anticipates negative trends or results.
- The reliance on a single product, LOQTORZI, for revenue growth may pose risks if its sales do not meet expectations or if competition increases in the oncology market.
FAQ
When will Coherus announce its second quarter 2025 financial results?
Coherus will release its second quarter 2025 financial results on August 7, 2025, after market close.
What time is the Coherus conference call on August 7, 2025?
The Coherus conference call will start at 5:00 p.m. EDT on August 7, 2025.
How can I access the Coherus conference call?
You can access the conference call by dialing 1-800-715-9871 for toll-free or 1-646-307-1963 for international calls.
Where can I find the webcast replay of the conference call?
A webcast replay will be available on Coherus' investor website at https://investors.coherus.com after the live call.
What is LOQTORZI and its significance?
LOQTORZI is Coherus' next-generation PD-1 inhibitor, a key product in their oncology pipeline aimed at treating various cancers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CHRS Insider Trading Activity
$CHRS insiders have traded $CHRS stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CHRS stock by insiders over the last 6 months:
- MATS WAHLSTROM sold 99,988 shares for an estimated $73,881
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CHRS Hedge Fund Activity
We have seen 53 institutional investors add shares of $CHRS stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 5,283,292 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,263,616
- MORGAN STANLEY removed 1,908,354 shares (-90.4%) from their portfolio in Q1 2025, for an estimated $1,540,041
- MILLENNIUM MANAGEMENT LLC added 1,850,349 shares (+176.3%) to their portfolio in Q1 2025, for an estimated $1,493,231
- TANG CAPITAL MANAGEMENT LLC added 1,447,362 shares (+39.7%) to their portfolio in Q1 2025, for an estimated $1,168,021
- DISCIPLINED GROWTH INVESTORS INC /MN removed 566,746 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $457,364
- AQR CAPITAL MANAGEMENT LLC removed 546,569 shares (-45.0%) from their portfolio in Q1 2025, for an estimated $441,081
- CITIGROUP INC added 541,280 shares (+112.6%) to their portfolio in Q1 2025, for an estimated $436,812
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CHRS Analyst Ratings
Wall Street analysts have issued reports on $CHRS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 04/29/2025
To track analyst ratings and price targets for $CHRS, check out Quiver Quantitative's $CHRS forecast page.
$CHRS Price Targets
Multiple analysts have issued price targets for $CHRS recently. We have seen 2 analysts offer price targets for $CHRS in the last 6 months, with a median target of $4.025.
Here are some recent targets:
- Douglas Tsao from HC Wainwright & Co. set a target price of $7.0 on 04/29/2025
- Ashwani Verma from UBS set a target price of $1.05 on 04/24/2025
Full Release
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Thursday, August 7, 2025, starting at 5:00 p.m. Eastern Daylight Time
To access the conference call:
- TOLL-FREE DIAL-IN: (800) 715-9871
- INTERNATIONAL DIAL-IN: (646) 307-1963
-
Conference ID 8712736
Webcast: https://edge.media-server.com/mmc/p/skv7e6d2
The press release with the second quarter 2025 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Please dial in 15 minutes early to ensure a timely connection to the call.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI ® (toripalimab-tpzi), growing revenues and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners’, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. CHS-114 is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in multiple Phase 1/2 and Phase 2 studies in patients with advanced solid tumors, including non-small cell lung cancer and hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com .
Coherus Contact Information
Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
[email protected]
